Erectile Dysfunction
Immunosuppression and risk of penile prosthesis complications: evidence from a large healthcare database.
- Details
Erectile dysfunction (ED) is common among men with solid organ transplant or other conditions requiring immunosuppression. Concern exists that immunosuppression status increases risk of penile prosthesis complications.
Vacuum Erection Devices in the Management Erectile Dysfunction: a systematic review.
- Details
Erectile dysfunction (ED) is a prevalent male sexual disorder associated with aging and comorbidities. Vacuum erection device(s) represent a non-invasive therapeutic option that can be proposed to patients with ED, either as monotherapy or in combination with pharmacological or psychosexual therapies.
Evaluating mental health risk and psychiatric care access in 18-40Â year old men with erectile dysfunction.
- Details
Mental health conditions (MHCs) are established risk factors for the development and severity of erectile dysfunction (ED), yet it is unclear whether patients are accessing psychiatric care.
The objectives of this study are to assess the proportion of young men with a MHC within 5 years before or after their ED diagnosis, determine their comorbidities, and characterize their interactions with psychiatric and psychological subspecialists before and after their ED diagnosis.
Sexual dysfunction in movement disorders: prevalence, clinical features, associated factors and management.
- Details
Sexual dysfunction is a common but insufficiently addressed non-motor symptom in movement disorders. While Parkinson's disease (PD) is the condition most frequently investigated, sexual dysfunction is also reported in Huntington's disease, dystonia, and other movement disorders.
Penile prosthesis implantation for patients with comorbid severe premature ejaculation and erectile dysfunction: a pilot cohort study.
- Details
Premature ejaculation (PE) and erectile dysfunction (ED) commonly show a bidirectional association. Pharmacological treatments for PE often result in high dropout rates due to limited efficacy and adverse events.
Unveiling Treatment Adherence Gaps in Psychogenic Versus Organic Erectile Dysfunction.
- Details
Erectile dysfunction (ED) cases can be classified as "primary organic" (PO-ED) or "primary psychogenic" (PP-ED) according to the most likely etiology. This study aimed to assess adherence to phosphodiesterase type 5 inhibitor (PDE5i) therapy in men with PP-ED and PO-ED.
Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 2 trial.
- Details
Simenafil, a new potent selective phosphodiesterase-5 inhibitor (PDE5i), has been developed for erectile dysfunction (ED) treatment.
To evaluate the efficacy and safety of simenafil therapy in patients with ED.
Physical Exercise for Erectile Dysfunction: A Mini review on Unresolved Controversies and the Path to Precision Prescription.
- Details
Erectile dysfunction (ED) is increasingly recognized as an early marker of systemic vascular disease, yet the role of exercise as a therapeutic intervention remains surrounded by significant controversy.
Therapeutic applications of phosphodiesterase inhibitors in male reproductive health: narrative review.
- Details
Phosphodiesterases (PDEs) are a family of enzymes that regulate intracellular levels of cyclic nucleotides, such as cyclic adenosine monophosphate and cyclic guanosine monophosphate. PDEs are considered key modulators of cellular signaling processes, including those governing male reproductive health.
Association of erectile dysfunction and male lower urinary tract symptoms in a Japanese cross-sectional survey.
- Details
The objective of this study is to evaluate the correlation between erectile dysfunction (ED) and lower urinary tract symptoms (LUTSs) using the International Index of Erectile Function-5 (IIEF-5) and the International Prostate Symptom Score (IPSS).